The Announcement of License and Collaboration Agreement with Hunan Fangsheng Pharmaceutical Co. Ltd.

LipoMedics Inc. (the “Lipo”) has entered into the License and Collaboration Agreement on July 10, 2016 with Hunan Fangsheng Pharmaceutical Co.Ltd., China (the “Fangsheng”), whereas Fangsheng has invested in Lipo for its newly issued common shares, representing 30% of the total share capital of Lipo after the investment. The material provisions include but not limited to assisting Fangsheng in upgrading its manufacturing plant to a cGMP manufacturing plant, licensing sales and distribution right in China to Fangsheng.

           Learn More >>


LipoMedics Inc. will present new data related to development of injectable Paclitaxel, phospholipid bound nanoparticle formulation at Nanoparticle Therapeutics 2016, 23rd-26th October, 2016 in Australia, BIT’s 6th Annual Symposium of Drug Delivery Systems 2016, 16th-19th November, 2016 in China, and 2016 AAPS Annual Meeting and Exposition, 13th -17th November 2016 in Denver, Colorado.

Learn More >>